Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
BLPH Bellerophon Therapeutics, Inc. daily Stock Chart
BLPH [NASD]
Bellerophon Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.39 Insider Own6.80% Shs Outstand34.86M Perf Week-3.60%
Market Cap37.30M Forward P/E- EPS next Y-0.96 Insider Trans0.00% Shs Float29.51M Perf Month-7.76%
Income-34.70M PEG- EPS next Q-0.16 Inst Own54.20% Short Float10.81% Perf Quarter-20.15%
Sales- P/S- EPS this Y58.20% Inst Trans22.06% Short Ratio9.51 Perf Half Y-24.11%
Book/sh-0.02 P/B- EPS next Y14.30% ROA-137.90% Target Price4.75 Perf Year-26.21%
Cash/sh0.43 P/C2.50 EPS next 5Y- ROE-385.40% 52W Range0.43 - 1.98 Perf YTD105.69%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-45.96% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low147.11% ATR0.08
Employees22 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)40.50 Volatility8.34% 7.14%
OptionableNo Debt/Eq- EPS Q/Q70.20% Profit Margin- Rel Volume0.93 Prev Close1.10
ShortableYes LT Debt/Eq- EarningsAug 15 BMO Payout- Avg Volume335.54K Price1.07
Recom1.50 SMA20-3.95% SMA50-13.37% SMA200-7.13% Volume311,653 Change-2.73%
Apr-17-17Initiated Ladenburg Thalmann Buy $4.50
Jan-20-17Initiated H.C. Wainwright Buy $5
Mar-22-16Reiterated Leerink Partners Outperform $11 → $9
Jul-27-15Reiterated FBR Capital Outperform $23 → $11
Mar-16-15Initiated FBR Capital Outperform $23
Sep-07-17 04:01PM  Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences GlobeNewswire
Sep-05-17 08:40AM  Bellerophon shares surge 20% premarket on positive results in trial of COPD treatment MarketWatch
08:30AM  Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease GlobeNewswire
Aug-07-17 11:57PM  Bellerophon Therapeutics posts 2Q loss Associated Press
08:00AM  Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Aug-03-17 08:30AM  Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) GlobeNewswire
May-22-17 04:01PM  Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference GlobeNewswire
May-16-17 08:00AM  Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Bellerophon Therapeutics Accesswire
May-15-17 08:22AM  Bellerophon Therapeutics posts 1Q loss Associated Press -5.10%
08:00AM  Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
May-10-17 08:00AM  Bellerophon Announces $3.0 Million Registered Direct Offering GlobeNewswire
May-01-17 08:01AM  Bellerophon to Present Positive Clinical Data on INOpulse® at the American Thoracic Society 113th International Conference GlobeNewswire
Apr-07-17 11:05AM  Bellerophon Slumps on Underwhelming INOpulse Data Investopedia -10.20%
07:00AM  Clinical Data on INOpulse® Presented at 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT) GlobeNewswire
Mar-27-17 08:00AM  Bellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation GlobeNewswire
Mar-21-17 09:30AM  The Difference Between Spectacular News and No News Accesswire
Mar-16-17 01:04PM  BELLEROPHON THERAPEUTICS, INC. Financials -5.13%
06:15AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
Mar-13-17 08:47AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
07:52AM  Bellerophon Therapeutics posts 4Q loss Associated Press
07:30AM  Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
06:20AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Feb-23-17 08:10AM  LifeSci Capital Initiates Coverage of Bellerophon Therapeutics Accesswire -7.69%
Jan-20-17 07:15AM  Coverage initiated on Bellerophon Therapeutics by H.C. Wainwright +5.51%
Jan-06-17 05:18PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Jan-04-17 08:38AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +16.43%
08:00AM  Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program GlobeNewswire
Dec-22-16 01:10PM  These 5 Stocks Under $10 Could Make You a Lot of Money TheStreet.com
01:10PM  These 5 Stocks Under $10 Could Make You a Lot of Money
Dec-12-16 05:26PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Nov-29-16 05:11PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a
Nov-23-16 06:30AM  Bellerophon Therapeutics, Inc. Announces $12 Million Public Offering GlobeNewswire -26.00%
Nov-15-16 05:09PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or
Nov-09-16 10:21AM  Bellerophon Therapeutics posts 3Q loss
Nov-08-16 07:08AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement -6.86%
07:03AM  Bellerophon Reports Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
06:40AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-01-16 02:09PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Bellerophon Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
12:50PM  Robbins Arroyo LLP is Investigating the Officers and Directors of Bellerophon Therapeutics, Inc. (BLPH) on Behalf of Shareholders Business Wire
10:15AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bellerophon Therapeutics, Inc. (BLPH) PR Newswire
Oct-31-16 08:00AM  Second Law Firm Hits Bellerophon (BLPH) at Investopedia
Oct-28-16 12:19PM  INVESTOR ALERT: Investigation of Bellerophon Therapeutics, Inc. Announced by Law Offices of Howard G. Smith Business Wire -8.00%
Oct-26-16 01:29PM  Law Firm Targets Bellerophon Therapeutics (BLPH) at Investopedia -14.86%
09:02AM  Johnson & Weaver, LLP Initiates Investigations of Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos Therapeutics, Inc., CommVault Systems, Inc. and Resource Capital Corp. PR Newswire
Sep-20-16 06:54AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
06:33AM  Bellerophon Therapeutics Announces Planned Management Transition by Year-End 2016 GlobeNewswire
Sep-06-16 06:37AM  Bellerophon to Present at the 18th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire -9.03%
Aug-09-16 07:02AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
06:41AM  Bellerophon Therapeutics posts 2Q loss
06:33AM  Bellerophon Reports Second Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
Jul-27-16 07:54AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.68%
Jul-25-16 12:05PM  Bellerophon Gets Approval To Start Second Stage Study In PH-COPD
06:03AM  Bellerophon Receives Approval to Commence Phase 2 Trial in PH-COPD GlobeNewswire
Jun-17-16 04:53PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-16-16 06:44AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
06:03AM  Bellerophon Therapeutics Announces Enrollment of the First Patient in the INOvation-1 Phase 3 Clinical Trial for Pulmonary Arterial Hypertension (PAH) GlobeNewswire
May-27-16 04:34PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a
May-13-16 07:49AM  6 Stocks Under $10 Making Big Moves Higher at TheStreet
May-10-16 07:17AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement -9.68%
06:46AM  Bellerophon Therapeutics posts 1Q loss
06:33AM  Bellerophon Reports First Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
06:15AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Mar-21-16 09:44AM  Edited Transcript of BLPH earnings conference call or presentation 21-Mar-16 12:30pm GMT
08:30AM  Bellerophon Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
07:07AM  Q4 2015 Bellerophon Therapeutics Inc Earnings Release - Before Market Open
06:37AM  Bellerophon Reports 2015 Financial Results and Provides Business Update at noodls
06:30AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
06:03AM  Bellerophon Reports 2015 Financial Results and Provides Business Update GlobeNewswire
Mar-14-16 08:03AM  Bellerophon Therapeutics to Hold Full Year 2015 Financial Results Conference Call on Monday March 21, 2016 GlobeNewswire
Mar-04-16 05:33PM  Bellerophon Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference GlobeNewswire +14.85%
Mar-02-16 08:03AM  Bellerophon Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-23-16 03:41PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
08:03AM  Bellerophon Therapeutics Appoints Fabian Tenenbaum as Chief Financial Officer and Chief Business Officer GlobeNewswire
Feb-18-16 08:25AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-16-16 08:03AM  Bellerophon Therapeutics Appoints Mary Ann Cloyd as an Independent Board Member GlobeNewswire +6.90%
Feb-09-16 08:03AM  Bellerophon Therapeutics Announces Positive Data From the Final Analysis of the Phase 2 Long-Term Extension Study of INOpulse for Treatment of Pulmonary Arterial Hypertension GlobeNewswire +43.43%
Feb-03-16 08:03AM  Bellerophon to Participate in LEERINK Partners 5th Annual Global Healthcare Conference GlobeNewswire
Jan-21-16 08:03AM  Bellerophon Therapeutics Announces Notice of Intention to Grant a European Patent Supporting Its INOpulse Program GlobeNewswire
Jan-19-16 08:03AM  Bellerophon Therapeutics Receives EC Certification for New INOpulse® Drug-Device Delivery System GlobeNewswire
08:00AM  MicroCap Review Magazine Winter/Spring 2016 Issue Now Available Marketwired
Jan-12-16 05:01PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a
Dec-13-15 11:25AM  The Best and Worst IPO's of 2015 at Motley Fool
Dec-04-15 04:32PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
Nov-30-15 05:14PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Nov-16-15 10:48AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
Nov-12-15 08:40AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
06:03AM  Bellerophon Reports 2015 Third Quarter Operational and Financial Results GlobeNewswire
Oct-01-15 08:17AM  Due Diligence Report: Phase 2 Success; Phase 3 the Real Test Accesswire -14.26%
Sep-30-15 04:08PM  Squashed Takeovers And Positive Test Results Propelling These Stocks Higher at Insider Monkey +25.97%
07:03AM  Bellerophon Announces Functional Respiratory Imaging Data From Company Sponsored Clinical Trial of INOpulse(R) in COPD Patients With Pulmonary Hypertension Presented Today at the European Respiratory Society (ERS) International Congress GlobeNewswire
Sep-29-15 01:54PM  Hedge Funds Disagree with the Market on One of These Two Falling Stocks at Insider Monkey -13.26%
Sep-25-15 03:30PM  Bellerophon Presents Positive Interim Data on INOpulse +69.35%
02:46PM  These Stocks Are Surging but See Which Ones Hedge Funds Think are Worth Investing In at Insider Monkey
09:00AM  Bellerophon Therapeutics, Inc. Conference Call to discuss Positive Data from Interim Analysis of Phase 2 Long-Term Extension Study of INOpulse(R) for Treatment of Pulmonary Arterial Hypertension scheduled for 9:00 am ET today
08:01AM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-24-15 05:02PM  Bellerophon shares skyrocket on high blood pressure drug study at MarketWatch
04:30PM  Bellerophon Therapeutics Announces Positive Data From Interim Analysis of Phase 2 Long-Term Extension Study of INOpulse(R) for Treatment of Pulmonary Arterial Hypertension GlobeNewswire
Sep-22-15 08:00AM  StockNewsNow.com Publishes New SNNLive Video Interview with Bellerophon Therapeutics, Inc. Marketwired
Sep-17-15 04:32PM  BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Direc
Sep-15-15 08:07AM  Bellerophon Therapeutics Announces Leadership Team Changes GlobeNewswire
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Luehring JensDirectorDec 09Buy0.5620,00011,20039,860Dec 12 10:10 AM
open in yahoo | open in reuters | open in google